Two established molecular subtypes are identified by high expression of the ERG oncoprotein, due to structural DNA alterations that encode for fusion transcripts in approximately 1⁄2 of prostate cancers, and over-expression of SPINK1, which is purportedly found only in ERG-negative tumors. Here, ERG is linked to prostate carcinoma.